Introduction

Polycystic ovary syndrome (PCOS) is a heterogeneous disorder
Polycystic-appearing ovaries (PAO) on ultrasound have
which is characterized by the findings of hyperandrogenism been described in a variety of endocrinopathies and also and chronic anovulation (Yen, 1991; Lobo, 1991 Lobo, , 1995 . occur in ovulatory women. By some investigators this is However, there is controversy in this diagnosis, and others merely referred to as 'PCO' (polycystic ovaries). Although have considered the syndrome to occur as long as women there is controversy in this regard, we do not consider have the ultrasound findings of polycystic ovaries (PCO) women with PAO/PCO who have no known endocrine (Balen et al., 1995; Homburg, 1996) . It is known, nevertheless, disturbance to have polycystic ovary syndrome (PCOS) that polycystic ovaries occur in other disorders as well, whether and therefore prefer not to use the term 'PCO' which is or not androgen excess is present (Abdel- Gadir et al., 1992 ; often equated with PCOS. We studied 15 ovulatory women Shoham et al., 1992; Carmina, 1995) . Indeed PCO have been with normal-appearing (NAO) ovaries on ultrasound and found in 16-25% of 'normal' ovulatory women (Polson et al., 15 matched ovulatory women with PAO/PCO. Compared 1988; Clayton et al., 1992) . We have made a distinction to ovulatory women, 25 other women were studied who were between women with only the ultrasound findings and no considered to have PCOS. Of these, 15 were overweight and disorder, and PCOS which we view to be an endocrinopathy, 10 were of normal weight. All the PCOS women had serum which requires the existence of both hyperandrogenism and concentrations of luteinizing hormone (LH), testosterone, anovulation. Although we are aware that a spectrum of unbound testosterone, androstenedione and dihydroabnormalities exists and no clear line demarcates women with epiandrosterone sulphate (DHEAS) which were signific-PCOS from normal women, here we will attempt to describe antly higher (P Ͻ 0.01) than values in the normal women, differences and/or similarities between normal ovulatory regardless of ovarian morphology. These values were women with polycystic ovaries on ultrasound and those women similar in the two groups of ovulatory women with NAO with characteristic features of PCOS who are either of normal and PAO/PCO. Fasting insulin was elevated in women with body weight or who are overweight. While we prefer to PCOS with increased body weight (P Ͻ 0.01) and was refer to ovulatory women with merely the classic ultrasound higher than in ovulatory women with NAO and PAO/PCO appearance of PCO as having PAO (polycystic-appearing and than in women of normal weight with PCOS. Serum ovaries), to avoid confusion we will describe these patients as insulin-like growth factor (IGF)-I and binding protein 'PAO/PCO'. However, we do not wish to equate these patients (BP)-3 were similar in all groups but serum IGFBP-1 was (PAO/PCO) with those having PCOS and our data have been significantly (P Ͻ 0.01) lower in those women with PCOS collected to address the potential similarities and differences. with increased body weight, compared to all other groups.
Recently we have studied normal ovulatory women underCompared to values in ovulatory women with NAO, serum going ovarian stimulation for oocyte donation (Wong et al., IGFBP-1 was also significantly (P Ͻ 0.05) lower in women 1995). Although ovarian responses to gonadotrophins were with PAO/PCO and those women with PCOS of normal exaggerated in these normal women with PAO/PCO, fertilizaweight. These lower values were similar in women with tion and other fertility criteria were similar to those of women PAO/PCO and in normal weight women with PCOS. On an individual basis, an elevation of at least one serum with normal appearing ovaries (NAO). However, it remains unclear whether women with PAO/PCO only have altered androgen value was found in 33% of women with PAO/ PCO. These data confirm that increased body weight ovarian morphology and no endocrine disturbance or in fact represent a cryptic or unexpressed form of the syndrome, accentuates the metabolic alterations in PCOS, but suggest that subtle endocrine disturbances, similar to those that PCOS. Accordingly we postulated that by studying androgen and growth factor parameters characteristic of PCOS (Suikkari are found in PCOS, may be uncovered in up to a third of ovulatory women with PAO/PCO. It appears that a et al., 1989; Lobo, 1991; Carmina et al., 1995) 
Materials and methods
hormone agonist (GnRHa) (Lupron; TAP, Deerfield, IL, USA). The GnRHa was begun during the midluteal phase and once Subjects down-regulation was reached (serum oestradiol Ͻ 30 pg/ml) ovarian A total of 55 women was studied of whom 15 were ovulatory (mean stimulation using human menopausal gonadotrophins (HMG) age 28 Ϯ 1 years) and had proven fertility, no hirsutism or menstrual (Pergonal; Serono, Aubonne, Switzerland) was initiated with three disturbances and were found to have sonographic evidence of polyampoules (225 IU) given daily i.m. Human chorionic gonadotrophin cystic-appearing ovaries (Adams et al., 1986) . We used the following (HCG) 10 000 IU was given i.m.as soon as five or more follicles standard criteria for the ultrasound diagnosis of PAO/PCO and PCOS.
Ͼ18 mm in diameter were present or oestradiol concentrations Each woman had to have findings on both ovaries of ജ10 peripherally reached 5000 pg/ml. Blood samples for serum testosterone and oriented cysts (Ͻ8 mm) on a sonographic plane, increased ovarian androstenedione were obtained 12 h before and 36 h after HCG volume and increased stromal density. This diagnosis should not be administration. confused with the normal-sized multifollicular ovary or a morphologically normal ovary during any stage of follicular development. Assays These women were volunteers in the donor oocyte programme at the University of Southern California.
Serum LH, FSH, testosterone, non-sex hormone-binding globulin In addition, 15 ovulatory control women (mean age 28 Ϯ 1 years) bound testosterone (unbound testosterone), androstenedione and with normal-appearing ovaries on ultrasound (NAO), who were also DHEAS were measured by well-established radioimmunoassay enrolled in the donor oocyte programme, were studied. The ovulatory methods which were validated previously in our laboratory (Mishell groups (NAO and PAO/PCO) had completely normal, cyclic menstrual et al., 1971; Goebelsmann et al., 1974; Lobo et al., 1980) . function and consistently elevated luteal phase progesterone concenSteroid assays included extraction and celite chromatography. In trations.
the LH and FSH assays, the standard used was LER 907, which was Twenty-five women with PCOS (mean age 25 Ϯ 1 years) were referenced to the Second International Reference Preparation. studied, all of whom had hyperandrogenism and chronic anovulaAn acid ethanol extraction step was used to extract IGF-I which tion. In addition, these women all had PCO which met the ultrawas then quantified by radioimmunoassay using a commercial kit sound criteria listed above (Adams et al., 1986) . PAO/PCO and NAO from Nichols Institute (San Juan, Capistrano, CA, USA). Both subjects had normal body weight (mean BMI 21.1 Ϯ 0.6 and 20.7
IGFBP-1 and IGFBP-3 were quantified by immunoradiometric assay Ϯ 0.3 respectively) whereas women with PCOS were divided into and direct radioimmunoassay methods, respectively, using kits two groups: 10 had normal body weight (mean BMI 22.6 Ϯ 0.6) and obtained from Diagnostic Systems Laboratories (Webster, TX, USA). 15 had increased body weight (mean BMI 27 Ϯ 2).
Insulin was quantified by use of a direct radioimmunoassay kit (Diagnostic Systems Laboratories).
Protocol
In all assays, intra-assay and interassay coefficients of variation PCO were defined by the presence of 10 or more cysts, in one did not exceed 6 and 13% respectively. ultrasonographic plane, each 2-8 mm in diameter, arranged around a dense stroma (Adams et al., 1986) . These criteria were applied to the Statistics inclusion of both ovulatory women and those with PCOS for this All data are expressed as the mean Ϯ SE. Statistical differences study. During the midfollicular phase (days 5-8), after an overnight between groups were determined by analysis of variance. Correlafast, blood samples were obtained for luteinizing hormone (LH), tions were analysed using the Pearson product moment correlation. follicle stimulating hormone (FSH), testosterone, androstenedione, unbound testosterone, dihydroepiandrosterone sulphate (DHEAS), P Ͻ 0.05 was considered significant. In all groups, IGF-1 and IGFBP-3 were similar while fasting DHEAS which were similar to those of NAO women (Figure insulin was significantly (P Ͻ 0.01) higher in women with 1 and Table I ). Both groups of ovulatory women had values PCOS who had increased weight compared to PAO, women of LH, testosterone, unbound testosterone, androstenedione with NAO and normal weight women with PCOS ( Figure 3 ). and DHEAS which were significantly (P Ͻ 0.01) lower than Insulin concentrations were similar in the ovulatory groups those of PCOS (Figure 1 and Table I ). This was the case for and normal weight PCOS (Figure 3 ). Serum IGFBP-1 was both subgroups of women with PCOS (normal and increased significantly lower in the overweight PCOS group compared body weight). An increased individual value level of a hormonal to all other groups including the normal weight women with parameter was defined as one which exceeded 2SD from the PCOS (P Ͻ 0.05; Figure 3 ). However, serum IGFBP-1 was mean value of normal women with normal ovaries (NAO). also significantly (P Ͻ 0.05) lower in the PAO group and These upper limits for values in our patients with NAO were normal weight women with PCOS compared to the NAO 1.46 nmol/l for testosterone, 9.0 nmol/l for androstenedione group (Figure 3 ). No differences in serum IGFBP-1 were and 22.2 pmol/l for unbound testosterone. Only two PAO/PCO found between PAO/PCO and normal weight women with women had an elevation of all ovarian androgens (testosterone, PCOS. No correlation was found between serum values of unbound testosterone and androstenedione). These values were insulin and IGFBP-1 in NAO or PAO/PCO (r ϭ 0.15, NS) 2.07 and 1.85 nmol/l for testosterone, 14.0 and 11.2 nmol/l (r ϭ 0.25, NS), or in normal weight women with PCOS (r ϭ for androstenedione, and 26 and 24.6 pmol/l for unbound 0.31, NS). A negative correlation between insulin and IGFBPtestosterone. Two other PAO/PCO women had an elevation 1 (r ϭ 0.67, P Ͻ 0.01) was present in overweight women only of androstenedione at values of 11.1 and 11.9 nmol/l; with PCOS. and one PAO/PCO woman had an increase only of unbound Calculated IGF-I:IGFBP-3 ratios were similar in all groups testosterone (22.9 pmol/l). No PAO/PCO woman showed but the IGF-I:IGFBP-1 ratio was significantly (P Ͻ 0.01) an increase of serum DHEAS. After ovarian stimulation, higher in overweight women with PCOS compared with PAO testosterone and androstenedione responses as a group were and NAO women and normal weight women with PCOS. PAO/ similar in PAO/PCO and NAO women (Figure 2) . The upper PCO and normal weight women with PCOS had significantly (P limits in NAO after ovarian stimulation were 2.17 nmol/l for Ͻ 0.01) higher IGF-I:IGFBP-1 ratios when compared with the testosterone, and 20.3 nmol/l for androstenedione. Only the two PAO/PCO women with an increase of all ovarian androgens NAO group which served as the true control group. 
Discussion
with PCOS who had increased body weight. Interestingly, women with PAO/PCO and PCOS with normal body weight There has been controversy regarding the definition of PCOS.
had similar values of IGFBP-1 which, nevertheless, were also Although this diagnosis is often based solely on the ultrasonolower than values found in ovulatory women with normal graphic appearance of the ovaries, we have only used this ovaries (NAO) with similar body weight. These findings may diagnosis in women who exhibit endocrine features of the suggest that body weight contributes to the metabolic and disorder, namely anovulation and hyperandrogenism. Polyendocrine features of PCOS (increased serum insulin and cystic ovaries have been identified in patients having disorders lowered IGFBP-1) but do not completely explain the changes with apparently normal androgen status, as well as in normal of IGFBP-1. The lower concentrations of IGFBP-1 in PAO/ ovulatory women (Polson et al., 1988; Clayton et al., 1992;  PCO women and the normal weight women with PCOS may Abdel Gadir et al., 1992) . Although it has been suggested that be the result of a mild insulin resistance. It has been shown these patients have some endocrine abnormalities similar to in PCOS that a mild insulin resistance may exist with normal those found in classic PCOS (Polson et al., 1988; Pache et al., body weight and normal basal insulin concentrations (Dunaif 1993) , no definitive studies have been performed to our et al., 1989; Carmina et al., 1992) . knowledge in women who are completely normal, apart from
In addition, other possibilities may be considered. The this ovarian morphological alteration.
decrease of serum IGFBP-1 could represent the manifestation In this study, we had the opportunity to evaluate 15 normal of an incompletely expressed genetic disorder which, in its ovulatory women with PAO/PCO. These women, while normal complete form (associated with increased insulin secretion), participants in an oocyte donation programme, were selected would result in classic PCOS. For several years it has been for evaluation to assess whether the morphological appearance considered that PCOS has a genetic mode of inheritance of PAO/PCO may be associated with PCOS. We found that (Hague et al., 1988) although no characteristic pattern of cryptic hyperandrogenism was not the rule in these women inheritance has been uncovered (Jahanfor et al., 1995) . It is and that a clear hyperandrogenic state (increases of testosterone, possible that PCOS is a polygenic syndrome and that women unbound testosterone and androstenedione and an increased with PAO/PCO represent an incompletely expressed form of androgen response to gonadotrophins) was observed in only the syndrome. Consistent with this hypothesis were the findings two out of 15 PAO/PCO women (13.3%). Three other PAO/ of reduced IGFBP-1 both in normal PAO/PCO women and PCO women had solitary increases in unbound testosterone or in PCOS. androstenedione. Nevertheless one could conclude that taken If a genetic predisposition, directly or mediated via hypertogether, up to 33% of normal ovulatory women with PAO/ insulinaemia, were to lead to reduced IGFBP-1, how does this PCO may have increased androgen secretion.
relate to PAO/PCO? At least one possibility is that small A characteristic endocrine feature of patients with PCOS is increases in IGF-1 might alter the balance between follicular a low concentration of IGFBP-1 (Suikkari et al., 1989; Carmina recruitment and follicular atresia without significantly increaset al., 1995) . In PCOS, this finding has been thought to be ing ovarian androgen secretion. It is known that IGF-1 within related to hyperinsulinaemia and/or obesity (Suikkari et al., the ovary is an important factor for the survival of ovarian 1988; Conover et al., 1992) . However, recently we have follicle cells (Hsueh et al., 1994) and may be involved in the observed that the control of IGFBP-1 secretion may also process of atresia. Interestingly, it has been reported that 'cystic be abnormal in PCOS . The normal ovaries' may result from a decreased rate of follicular atresia ovulatory women with PAO/PCO in this study had lower concentrations of IGFBP-1 although not as low as the women (Erickson, 1992 
